1.
|
8 p, 390.2 KB |
Utilisation and Off-Label Prescriptions of Respiratory Drugs in Children
/
Schmiedl, Sven (Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Germany) ;
Fischer, Rainald (Pneumologische Praxis München-Pasing, Munich, Germany) ;
Ibáñez, Luisa (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Fortuny, Joan (Novartis Farmacéutica (Barcelona, Catalunya)) ;
Klungel, Olaf H. (Utrecht University, the Netherlands) ;
Reynolds, Robert (Epidemiology, Pfizer, New York, United States of America) ;
Gerlach, Roman (National Association of Statutory Health Insurance Physicians of Bavaria, Munich, Germany) ;
Tauscher, Martin (National Association of Statutory Health Insurance Physicians of Bavaria, Germany) ;
Thürmann, Petra (Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Germany) ;
Hasford, Joerg (Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet, Munich, Germany) ;
Rottenkolber, Marietta (Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet, Munich, Germany)
Respiratory drugs are widely used in children to treat labeled and non-labeled indications but only some data are available quantifying comprehensively off-label usage. Thus, we aim to analyse drug utilisation and off-label prescribing of respiratory drugs focusing on age- and indication-related off-label use. [...]
2014 - 10.1371/journal.pone.0105110
PloS one, Vol. 9 (september 2014)
|
|
2.
|
16 p, 1.2 MB |
Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015) : A cross-national drug utilization study
/
Ibáñez, Luisa (Universitat Autònoma de Barcelona) ;
Sabaté, Mònica (Universitat Autònoma de Barcelona) ;
Vidal Guitart, Xavier (Universitat Autònoma de Barcelona) ;
Ballarín, Elena (Hospital Universitari Vall d'Hebron) ;
Rottenkolber, Marietta (Klinikum der Universität München) ;
Schmiedl, Sven (Helios University Hospital Wuppertal) ;
Heeke, Andreas (AOK NORDWEST) ;
Huerta, Consuelo (Agencia Española de Medicamentos y Productos Sanitarios) ;
Martin Merino, Elisa (Agencia Española de Medicamentos y Productos Sanitarios) ;
Montero, Dolores (Agencia Española de Medicamentos y Productos Sanitarios) ;
Leon-Muñoz, Luz María (Agencia Española de Medicamentos y Productos Sanitarios) ;
Gasse, Christiane (Aarhus University) ;
Moore, Nicholas (INSERM CIC1401, Université de Bordeaux) ;
Droz, Cécile (INSERM CIC1401, Université de Bordeaux) ;
Lassalle, Régis (INSERM CIC1401, Université de Bordeaux) ;
Aakjær, Mia (University of Copenhagen) ;
Andersen, Morten (University of Copenhagen) ;
De Bruin, Marie Louise (University of Copenhagen) ;
Groenwold, Rolf (Leiden University Medical Center) ;
van den Ham, Hendrika A. (Universiteit Utrecht, David de Wiedgebouw) ;
Souverein, Patrick (Universiteit Utrecht, David de Wiedgebouw) ;
Klungel, Olaf (University Medical Center Utrecht) ;
Gardarsdottir, Helga (University of Iceland) ;
Universitat Autònoma de Barcelona ;
Hospital Universitari Vall d'Hebron
To estimate the incidence of direct oral anticoagulant drug (DOAC) use in patients with nonvalvular atrial fibrillation and to describe user and treatment characteristics in 8 European healthcare databases representing 6 European countries. [...]
2019 - 10.1111/bcp.14071
British Journal of Clinical Pharmacology, Vol. 85 (september 2019) , p. 2524-2539
|
|
3.
|
9 p, 3.3 MB |
Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007-2010
/
Ferrer, Pili (Fundació Institut Català de Farmacologia) ;
Sabaté, Mònica (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Ballarín, Elena (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Fortuny, Joan (RTI Health Solutions) ;
Rottenkolber, Marietta (Diabetes Research Group, Medical Department 4, University Hospital Munich, Campus Innenstadt, Ludwig-Maximilians-Universität, Ziemssenstr 1) ;
Schmiedl, Sven (Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten-Herdecke University, Alfred Herrhausen-Strasse 50) ;
Laporte Rosselló, Joan-Ramón (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Ibáñez, Luisa (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Fundació Institut Català de Farmacologia
The online version of this article (doi:10. 1186/s40064-015-1398-4) contains supplementary material, which is available to authorized users.
2015 - 10.1186/s40064-015-1398-4
SpringerPlus, Vol. 4 (october 2015)
|
|
4.
|
10 p, 619.3 KB |
Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
/
Rottenkolber, Marietta (Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet) ;
Fischer, Rainald (Pneumologische Praxis Muenchen - Pasing, Munich, Germany) ;
Ibáñez, Luisa (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Fortuny, Joan (Novartis Farmaceutica SA) ;
Reynolds, Robert (Pfizer Research & Development, New York, USA) ;
Amelio, Justyna (Amgen Ltd, Uxbridge, UK) ;
Gerlach, Roman (National Association of Statutory Health Insurance Physicians of Bavaria, Munich, Germany) ;
Tauscher, Martin (National Association of Statutory Health Insurance Physicians of Bavaria, Munich, Germany) ;
Thürmann, Petra (Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Germany) ;
Hasford, Joerg (Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet) ;
Schmiedl, Sven (Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Germany)
After the SMART trial evaluating the safety of salmeterol (long-acting beta-2-agonist (LABA)) in asthma patients, regulatory actions were taken to promote a guideline-adherent prescribing of LABA only to patients receiving inhaled corticosteroids (ICS). [...]
2015 - 10.1186/s12890-015-0051-x
BMC Pulmonary Medicine, Vol. 15 (may 2015)
|
|